Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Deferiprone Delayed Release vs Oral Solution
NCT02442310Phase 1Completed
- Sponsor
- ApoPharma Inc.
- Start
- May 2015
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of deferiprone in iron overload (4 arms), sponsored by ApoPharma Inc. Primary endpoints: Maximum Observed Serum Concentration at 24 hours, Time to Maximum Observed Serum Concentration at 24 hours and 1 more. Started May 2015; status: completed.
02
Drugs
deferiprone
03
Conditions
iron overload
Beyond the preview
Go deeper on NCT02442310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02442310.